<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080947</url>
  </required_header>
  <id_info>
    <org_study_id>002017</org_study_id>
    <nct_id>NCT04080947</nct_id>
  </id_info>
  <brief_title>The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis</brief_title>
  <official_title>The Leukotriene Receptor Antagonist Montelukast in the Treatment of Non-alcoholic Steatohepatitis: A Proof-of-Concept, Randomized, Double-Blind, Placebo-Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sadat City University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sadat City University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to evaluate the safety and efficay of Montelukast in&#xD;
      treatment of patients with fatty liver disease.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fibro-scan score</measure>
    <time_frame>At baseline and after 12 weeks of intervention</time_frame>
    <description>change in liver stiffness measurement (Fibro-scan score)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Panel</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Alanine aminotransferase (ALT) and Aspartate Aminotransferase (AST) will be evaluated in U/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>HOMA-IR</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Homeostatic Model Assessment of Insulin Resistance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>8-OHdG</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Serum level of 8-OHdG</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TNF-Alpha</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Serum level of TNF-Alpha</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hyaluronic acid</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Serum level of hyaluronic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TGF-β1</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Serum level of TGF-β1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of drugs tolerability: Side effects</measure>
    <time_frame>after 12 weeks of intervention</time_frame>
    <description>Side effects of montelukast</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Steatohepatitis, Nonalcoholic</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>26 patients will receive placebo (Control group)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Montelukast group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>26 patients will receive montelukast 10 mg/ day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control group</intervention_name>
    <description>patients received matching-image placebo once daily at bedtime for 12 weeks.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Montelukast group</intervention_name>
    <description>patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.</description>
    <arm_group_label>Montelukast group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - The inclusion criteria were adult patients (age &gt;18 years old) of both sexes,&#xD;
        overweight/obese subjects with presence of evidence of hepatic steatosis by imaging&#xD;
        (increased liver echogenicity, stronger echoes in the hepatic parenchyma, vessel blurring,&#xD;
        and narrowing of the lumen of the hepatic veins). Patients with mild to moderate elevation&#xD;
        in aminotransferase activities (&gt; 2 but &lt;5 times upper limit of normal), hepatic steatosis&#xD;
        index (HIS) &gt;36, Fibro-scan score &gt;7 kpa and &lt;12.5 kpa (F0-F3), and HAIR score of 2 or 3&#xD;
        were included in the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        - The exclusion criteria included smokers, patients with secondary hepatic fat accumulation&#xD;
        which results from using steatogenic medications or hereditary disorders. Alcohol&#xD;
        consumers, patients with Wilson's disease, hemochromatosis, viral hepatitis, decompensated&#xD;
        liver disease, inflammatory diseases, diabetes, depression and patients with other comorbid&#xD;
        conditions that elevate transaminases (congestive heart failure and malignancy) pregnancy&#xD;
        and lactating women were excluded&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Faculty of Medicine</name>
      <address>
        <city>Shibīn Al Kawm</city>
        <state>Menoufia</state>
        <zip>13829</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 31, 2019</study_first_submitted>
  <study_first_submitted_qc>September 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sadat City University</investigator_affiliation>
    <investigator_full_name>Mahmoud Samy Abdallah</investigator_full_name>
    <investigator_title>Lecturer of Clinical Pharmacy, PhD.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Montelukast</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

